Orphan drug applications skyrocket as Big Pharma carves out niche

01/31/2013 | Wall Street Journal, The

Rare diseases are attracting renewed interest as multinational drugmakers seek to take advantage of easier approval pathways and high prices for orphan drugs. Firms including Sanofi, Pfizer and GlaxoSmithKlein are working on or have already secured approval for drugs that treat rare conditions. The progress in understanding the molecular base for these diseases has also spurred drugmakers' interest.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ